- Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV1 molecular glue degrader
- EVO301 late-breaking EADV data demonstrate clear therapeutic signal and favorable safety and tolerability profile, supporting Phase 2b trial in AD expected for mid-2027 initiation
- Additional clinical milestones expected in 2027, including initiation of the EVO570 Phase 1 trial in early 2027, the EVO301 Phase 2 trial in ulcerative colitis and the EVO646 Phase 1 study
- Key 2027 data expected to include Phase 1 healthy volunteer and biomarker data for EVO570 and EVO646, and top-line Phase 2b migraine data for EVO756
- Strong balance sheet with cash runway into 2H 2029 to deliver multiple key milestones across the pipeline
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--November 12, 2026--
Evommune, Inc. $(EVMN)$ (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.
"We have built a portfolio of differentiated immunology assets spanning biologics and small molecules, each aimed at a distinct upstream driver of chronic inflammation. The in-licensing of EVO570 expands our reach into T- and B-cell-driven autoimmune diseases, while the EADV data strengthen our conviction that EVO301 has the potential to become a foundational therapy in atopic dermatitis, if approved," said Luis Peña, President and Chief Executive Officer at Evommune. "As we advance EVO301 into Phase 2b and expand into ulcerative colitis, 2027 will be a year of execution and clinical catalysts for Evommune, with additional new clinical studies across EVO646 and EVO570 and Phase 2b migraine top-line data expected from EVO756. With a strong balance sheet and an experienced team, we believe we are well positioned to deliver on these milestones and create meaningful value for patients and stockholders."
Recent Business Highlights and Upcoming Milestones
EVO301 -- Injectable IL-18 Binding Protein Fusion Protein
Anti-serum albumin Fab-associated (SAFA) IL-18BP fusion protein designed to neutralize IL-18 activity, which is aberrantly upregulated in many inflammatory and autoimmune diseases. Targeting IL-18 offers a novel upstream approach that extends beyond Th2 to address multiple inflammatory pathways, with the potential to serve a broad range of patients.
-- Presented Data Showing EVO301's Clear Therapeutic Signal, Favorable
Safety and Tolerability Profile at EADV Congress: In October 2026,
Evommune presented additional data from its Phase 2a proof-of-concept
trial of EVO301 in adults with moderate-to-severe atopic dermatitis (AD)
in a late-breaking oral presentation at the European Academy of
Dermatology and Venereology (EADV) 2026 Congress. With only two
injections, EVO301 met the trial's primary endpoint, achieving a 55%
least-squares mean reduction from baseline in Eczema Area and Severity
Index $(EASI)$ at Week 12, eight weeks after the last dose, compared with
22% on placebo (p<0.01); responses continued to deepen throughout the
off-drug period. Biomarker analyses confirmed broad anti-inflammatory
activity across the Th2, Th1, Th17 and Th22 pathways, and EVO301 was well
tolerated, with no observed treatment-related serious or severe adverse
events and no conjunctivitis. (Press release).
-- Global Phase 2b AD Trial Expected to Initiate in Mid-2027: Evommune
continues to advance EVO301 toward the initiation of a Phase 2b
dose-ranging trial in approximately 200 adults with moderate-to-severe
AD. Nonclinical toxicology studies with a subcutaneous formulation of
EVO301 will initiate in early 2027. Dosing regimens have been selected
for the planned Phase 2b trial, where three dosing regimens of EVO301
will be tested against placebo for 16 weeks, with an off-drug follow-up
period out to 24 weeks.
-- Phase 2 Proof-of-Concept Trial in Ulcerative Colitis (UC) Planned to
Initiate in First Quarter of 2027, Data Expected in 2028: Evommune plans
to initiate a Phase 2 proof-of-concept trial of EVO301 in UC in the first
quarter of 2027, extending development beyond dermatology to inflammatory
bowel disease, where IL-18 and IL-22 are upregulated. In the Phase 2a AD
trial, EVO301 meaningfully reduced IL-22, a cytokine implicated in the
epithelial barrier dysfunction that is a key attribute of UC, and
inflammatory bowel disease more generally.
EVO756 -- Oral MRGPRX2 Antagonist for Migraine Prophylaxis
Potent and highly selective small-molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor found predominantly on peripheral sensory neurons and mast cells.
-- Top-Line Data from Phase 2b Migraine Trial Anticipated in Second Half
of 2027: The Phase 2b dose-ranging trial of EVO756 in adults with
refractory migraine is underway, with top-line data expected in the
second half of 2027. In September 2026, Evommune discontinued development
of EVO756 in AD after a Phase 2b trial did not meet its primary endpoint.
(Press release).
EVO570 -- Oral VAV1 Molecular Glue Degrader
Oral, highly selective VAV1 molecular glue degrader (MGD) designed to deliver JAK-like efficacy in autoimmune disease. VAV1 is a signaling protein, largely restricted to immune cells, that drives T- and B-cell activation across a wide range of chronic inflammatory diseases.
-- In-Licensed EVO570 from Hinova Pharmaceuticals Inc. (SSE: 688302,
"Hinova"): In November 2026, Evommune entered into an exclusive license
agreement with Hinova granting Evommune worldwide rights outside of
Greater China to develop, manufacture and commercialize EVO570 (formerly
HC118). Evommune paid $30 million upfront, consisting of $20 million in
cash and $10 million in the form of pre-funded warrants to purchase
Evommune common stock. Hinova is eligible to receive additional
development, regulatory and commercial milestones, as well as tiered
royalties on net sales outside Greater China. (Press release).
-- Phase 1 Trial Expected to Begin in Q1 2027: Investigational New Drug
(IND) applications have been submitted in China and opened in the United
States. A Phase 1 trial is expected to begin in the first quarter of 2027
with healthy volunteer and biomarker data expected mid-2027. Evommune
plans to initiate a Phase 2 program in rheumatoid arthritis in 2H 2027.
EVO646 -- Oral TLR7/8 Antagonist
Selective oral TLR7/8 antagonist with the potential to offer a more targeted approach to controlling upstream drivers of lupus and other interferon-, myeloid inflammation- and autoantibody-driven conditions.
-- Program to Enter the Clinic in the First Half of 2027: Evommune plans
to initiate a Phase 1 trial for EVO646 in the first half of 2027 with
healthy volunteer and biomarker data expected in the second half of 2027.
EVO646 was discovered through a partnership with Accutar Biotech. TLR7/8
inhibition has demonstrated significant clinical benefit in cutaneous and
systemic lupus erythematosus, and Evommune estimates approximately six
million patients across its initial potential indications.
-- Achieved Preclinical Development Milestone in Accutar Research
Collaboration: In November 2026, Accutar Biotech announced the
achievement of a preclinical development milestone in its multi-year,
multi-target research collaboration with Evommune. (Press release).
Corporate Updates
-- Announced Concurrent $30 Million Private Placement: In November 2026,
concurrent with the in-licensing of EVO570, Evommune entered into a
securities purchase agreement to sell 4,966,889 shares of its common
stock at $6.04 per share to a select group of dedicated healthcare
institutional investors, for gross proceeds of approximately $30 million.
Evommune intends to use the net proceeds to advance its clinical
development programs, including EVO570, and for general corporate
purposes. (Press release).
Third Quarter 2026 Financial Results
-- Cash, Cash Equivalents and Investments: As of September 30, 2026, the
Company had cash, cash equivalents and investments of $262.3 million,
compared to $216.7 million as of December 31, 2025.
-- Revenue: The Company did not generate any revenue for the three and
nine months ended September 30, 2026, compared to revenue of $10.0
million and $13.0 million for the three and nine months ended September
30, 2025, attributable to the Company's strategic collaboration with
Maruho for EVO756 in Japan.
-- Research and Development Expenses: Research and development expenses
were $24.6 million and $68.3 million for the three and nine months ended
September 30, 2026, compared to $19.6 million and $53.6 million for the
three and nine months ended September 30, 2025, primarily due to increase
in preclinical research expenses for undisclosed discovery programs and
personnel costs, and partially offset by a decrease in clinical trial
expenses.
-- General and Administrative Expenses: General and administrative
expenses were $8.8 million and $23.9 million for the three and nine
months ended September 30, 2026, compared to $3.7 million and $10.7
million for the three and nine months ended September 30, 2025.
-- Net Loss: Net loss totaled $30.9 million and $84.8 million for the
three and nine months ended September 30, 2026, compared to $12.5 million
and $40.6 million for the three and nine months ended September 30,
2025.
About Evommune, Inc.
Comments